Washam, Jeffrey B. http://orcid.org/0000-0002-0331-9581
Hohnloser, Stefan H.
Lopes, Renato D.
Wojdyla, Daniel M.
Vinereanu, Dragos
Alexander, John H.
Gersh, Bernard J.
Hanna, Michael
Horowitz, John
Hylek, Elaine M.
Xavier, Denis
Verheugt, Freek W. A.
Wallentin, Lars
Granger, Christopher B.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
https://doi.org/10.1016/j.ahj.2013.05.016
Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
https://doi.org/10.1016/j.ahj.2014.06.005
Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
https://doi.org/10.1016/j.ahj.2009.07.035
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
https://doi.org/10.1016/s0140-6736(16)00741-8
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
https://doi.org/10.1136/openhrt-2020-001471
Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
https://doi.org/10.1136/openhrt-2018-000908
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial
https://doi.org/10.1007/s11239-019-01823-y
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
https://doi.org/10.1007/s40256-022-00524-x
Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease
https://doi.org/10.1136/heartjnl-2017-312272
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60986-6
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
https://doi.org/10.1016/j.ahj.2014.09.006
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
https://doi.org/10.1136/heartjnl-2018-313351
Documentation of study medication dispensing in a prospective large randomized clinical trial: Experiences from the ARISTOTLE Trial
https://doi.org/10.1016/j.ahj.2013.05.025
Funding for this research was provided by:
Bristol-Myers Squibb
Pfizer
Article History
First Online: 21 February 2019
Compliance with ethical standards
:
: Washam: None. Hohnloser: Consulting/Lecture fees from Boehringer Ingelheim, St Jude Medical, Sanofi Aventis, Cardiome. Lopes: Research grants from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer; Consultant/Advisory Board fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Merck, Portola, GlaxoSmithKline, Pfizer. Wojdyla: None. Vinereanu: Research grants from GlaxoSmithKline, Pfizer, Bristol-Myers Squibb. Alexander: Institutional research grants from Bristol-Myers Squibb, Boehringer Ingelheim, CryoLife, CSL Behring, the US Food and Drug Administration, the National Institutes of Health, Tenax Therapeutics, and VoluMetrix; Consulting fees/Honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck, Novo Nordisk Pharmaceuticals, Pfizer, Portola Pharmaceuticals, VA Cooperative Studies Program, and Zafgen. Gersh: Consultant/Advisory Board fees from Boston Scientific Corporation, Cardiovascular Research Foundation, Coretherapix, Duke Clinical Research Institute, Duke University, Icahn School of Medicine at Mount Sinai, Janssen Research and Development, Janssen Scientific Affairs, Kowa Research Institute, Inc., Medtronic, Mount Sinai St. Luke’s, Sirtex Medical Limited, Teva Pharmaceutical Industries, Thrombosis Research Institute. Hanna: Employee of Bristol-Myers Squibb at the time the trial was conducted. Horowitz: None. Hylek: Research grants from Bristol Myers Squibb/Pfizer, Janssen; Consulting fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Janssen, Medtronic, Portola. Xavier: None. Verheugt: Consulting fees/Honoraria from Bayer Healthcare, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo. Wallentin: Institutional research grants from Bristol-Myers Squibb/Pfizer, AstraZeneca, Merck, Boehringer Ingelheim, and GlaxoSmithKline; Consulting fees from GlaxoSmithKline, Bristol-Myers Squibb/Pfizer, Abbott, AstraZeneca, and Boehringer Ingelheim. Granger: Research grants from Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi, GlaxoSmithKline, Janssen, Medtronic Foundation, Novartis, Pfizer, The Medicines Company; Consultant/Advisory Board fees from AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc, GlaxoSmithKline, Hoffman LaRoche, Janssen, Medtronic, Novartis, Pfizer, The Medicines Company, Verseon.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.